- Conditions
- Postmenopausal Women With Osteoporosis
- Interventions
- Romosozumab, Alendronate, Placebo to Romosozumab, Placebo to Alendronate
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 55 Years to 90 Years · Female only
- Enrollment
- 4,093 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 1,163
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypercholesterolemia
- Interventions
- Evolocumab, Placebo, Atorvastatin, Ezetimibe, Diet Only
- Biological · Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 905 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 33 more
- Conditions
- Prurigo Nodularis
- Interventions
- Nemolizumab, Placebo
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 22
- States / cities
- Fountain Valley, California • San Diego, California • Washington D.C., District of Columbia + 19 more
- Conditions
- Hypercholesterolemia
- Interventions
- Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
- Conditions
- Anemia
- Interventions
- placebo, epoetin alpha, Niferex
- Drug
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 2
- States / cities
- Cranbury, New Jersey • East Brunswick, New Jersey
- Conditions
- Submental Fat, Healthy
- Interventions
- ATX-101, Placebo
- Drug
- Lead sponsor
- Kythera Biopharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 13
- States / cities
- San Diego, California • Englewood, Colorado • Coral Gables, Florida + 9 more
- Conditions
- Breast Cancer, Mastectomy, Anesthesia, Local, Narcotic Use
- Interventions
- regional nerve block with local anesthesia of bupivacaine with steroid, Placebo regional nerveblock with normal saline
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Lunsekimig, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 942 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 73
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Surprise, Arizona + 59 more
- Conditions
- Smoking Cessation, Smoking Behaviors
- Interventions
- Tirzepatide, Placebo
- Drug · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 1 more
- Conditions
- Obesity
- Interventions
- Semaglutide, Tirzepatide, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Inflammation, Psoriasis
- Interventions
- anti-IL-20, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • Skokie, Illinois + 11 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- SAR440340, Placebo, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care, Any Long Acting Beta Agonist as prescribed by treating physician as standard of care, Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care, Any short-acting β agonist as prescribed by treating physician as standard of care
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Riverside, California • Rolling Hills Estates, California + 13 more
- Conditions
- Alzheimers Disease
- Interventions
- Gantenerumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more
- Conditions
- Crohn's Disease
- Interventions
- certolizumab pegol 400 mg, Placebo
- Biological · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 51 more
- Conditions
- Axial Spondyloarthritis
- Interventions
- Placebo, Ustekinumab 45 mg, Ustekinumab 90 mg, Golimumab 50 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 19
- States / cities
- Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 16 more
- Conditions
- Plaque-type Psoriasis
- Interventions
- Placebo, Secukinumab 150mg, Secukinumab 300mg
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more
- Conditions
- Asthma
- Interventions
- Dupilumab, Placebo (for Dupilumab), Fluticasone/Salmeterol combination therapy, Fluticasone monotherapy, Albuterol, Levalbuterol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 50
- States / cities
- Anaheim, California • Long Beach, California • Los Angeles, California + 42 more
- Conditions
- HIV/AIDS, Lipohypertrophy, Obesity
- Interventions
- Semaglutide Injectable Product, Placebo
- Drug
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Charleston, South Carolina
- Conditions
- Sjögren's Syndrome, Sjogren's Syndrome
- Interventions
- SAR441344, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- DeBary, Florida • Duncansville, Pennsylvania • Memphis, Tennessee + 1 more
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis
- Interventions
- SR34006 (idraparinux sodium) Injection
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 32
- States / cities
- Bay Pines, Florida • Brandon, Florida • Jacksonville, Florida + 23 more
- Conditions
- Hepatitis C Virus
- Interventions
- BMS-790052, Placebo, peginterferon alfa-2a, ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 35
- States / cities
- Montgomery, Alabama • La Jolla, California • Los Angeles, California + 28 more
- Conditions
- Osteogenesis Imperfecta (OI)
- Interventions
- AGA2115, Placebo
- Drug · Other
- Lead sponsor
- Angitia Incorporated Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Wilmington, Delaware + 6 more
- Conditions
- Atopic Dermatitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more
- Conditions
- Chronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
- Interventions
- NSAID, Tanezumab 2.5 mg, Tanezumab 5 mg
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,021 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 299
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more